Related Experiment Videos
Chemotherapy and thrombosis in gynecologic malignancy
G F von Tempelhoff1, K Pollow, D Schneider
1Department of Obstetrics and Gynecology, City Hospital of Ruesselsheim, Germany.
Summary
Thromboembolism, or blood clots, are a serious risk for gynecologic cancer patients undergoing chemotherapy. Prophylaxis is recommended for high-risk individuals, showing reduced deep vein thrombosis (DVT) rates.
Area of Science:
- Gynecologic Oncology
- Hematology
- Oncology
Background:
- Thromboembolism is a significant complication in gynecologic malignancy, with deep vein thrombosis (DVT) incidence potentially underestimated due to asymptomatic cases.
- Risk factors beyond chemotherapy, including menopausal status, BMI, and prior surgery, likely contribute to thrombosis development.
Purpose of the Study:
- To evaluate the risk factors and prevention strategies for thromboembolism in patients with gynecologic malignancy undergoing chemotherapy.
- To assess the efficacy of thrombosis prophylaxis in reducing DVT incidence.
Main Methods:
- Review of existing literature and clinical data on DVT incidence and risk factors in gynecologic cancer patients.
- Analysis of the role of coagulation tests and pre-chemotherapy evaluation.
- Consideration of patient subgroups with venous access devices and specific risk factors for targeted prophylaxis.
Main Results:
- The average DVT incidence during chemotherapy is approximately 5%, but clinical manifestation is often absent.
- Patients with venous access devices are at particularly high risk for DVT.
- Thrombosis prevention trials demonstrated a significant reduction in DVT rates with anticoagulant therapy.
Conclusions:
- Pre-chemotherapy coagulation status evaluation is recommended over continuous monitoring.
- Thrombosis prophylaxis should be reserved for a select group of high-risk patients.
- Anticoagulant therapy is effective in reducing DVT in patients undergoing chemotherapy for gynecologic malignancy.